Pharmaceutical Technology on MSN17h
EC approves CSL’s Andembry to stop hereditary angioedema attacks
CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
The American Journal of Managed Care6y
Severity of Hereditary Angioedema, Prevalence, and Diagnostic Considerations
12 As with other diseases that are characterized by acute attacks, such as asthma, the burden of HAE is not only economic but also impacts the patient’s quality of life, education, relationships ...
pharmaphorum1d
EU approves CSL's once-monthly HAE drug Andembry
CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...
Hosted on MSN9mon
‘I looked like The Elephant Man’: Life with extreme swelling disease HAE
That’s how my parents knew that I had hereditary angioedema (HAE) – a rare disease that I’d inherited from my dad. HAE is caused by a deficiency in C1 inhibitor (C1-INH) in the blood and it ...
pharmaphorum7y
Shire plans filing for HAE drug after phase 3 success
Shire noted that the study was representative of the full HAE disease spectrum. Overall, 52% of the study’s 125 patients experienced three or more attacks per month at baseline, 65% of patients ...
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...
PMLive1d
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...